Wall Street is positive on Jazz Pharmaceuticals PLC (JAZZ). On average, analysts give JAZZ a Strong Buy rating. The average price target is $160.571, which means analysts expect the stock to rise by 40.94% over the next twelve months.
That average ranking earns JAZZ an Analyst Rating of 70, which is better than 70% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.
InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.
What's Happening With Jazz Pharmaceuticals PLC Stock Today?
Jazz Pharmaceuticals PLC (JAZZ) stock is down -5.57% while the S&P 500 is up 0.72% as of 3:19 PM on Monday, Jun 8. JAZZ has fallen -$6.72 from the previous closing price of $120.65 on volume of 1,060,358 shares. Over the past year the S&P 500 is higher by 11.44% while JAZZ has fallen -11.78%. JAZZ earned $4.81 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 23.68.
